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Abstract
Platelets contain not only proteins needed for hemostasis but also many growth
factors that are required for organ development, tissue regeneration, and repair.
Thrombocytopenia, which is frequently observed in patients with chronic liver disease
(CLD) and cirrhosis, is due to various causes, such as decreased thrombopoietin pro-
duction and accelerated platelet destruction caused by hypersplenism; however, the
relationship between thrombocytopenia and hepatic pathogenesis and the role of
platelets in CLD are poorly understood. Thus, in this paper, the experimental evidence
for platelets improving liver ﬁbrosis and accelerating liver regeneration is summarized
and addressed based on studies conducted in our laboratory and current progress
reports from other investigators. Platelets improve liver ﬁbrosis by inactivating hepatic
stellate cells to decrease collagen production. The level of intracellular cAMP is
increased by adenosine through its receptors on hepatic stellate cells, thereby
resulting in inactivation of these cells. Adenosine is produced by degradation of ade-
nine nucleotides, which are stored in abundance within the dense granules of plate-
lets. The regenerative effect of platelets in the liver consists of three mechanisms: a
direct effect on hepatocytes, a cooperative effectwith liver sinusoidal endothelial cells,
and a collaborative effectwith Kupffer cells. Based on these experiments, a clinical trial
suggested that the increase in platelets induced by platelet transfusion improved liver
function in patients with CLD in a clinical setting.We highlight the current knowledge
concerning the role of platelets in CLD and expect to open a novel avenue for applica-
tion of these clinical therapies to treat liver disease.
Introduction
Chronic liver disease (CLD) is a major cause of mortality and
morbidity in many countries,1 and cirrhosis is the end stage of
CLD. Cirrhosis carries a poor prognosis and an increased risk of
carcinogenesis.2 Liver ﬁbrosis represents the consequence of a
sustained wound-healing response to chronic liver injury induced
by a variety of causes, including viral infection, alcohol abuse,
autoimmune disorders, drug use, cholestasis, and metabolic
diseases. 3Currently, liver transplantation is still the only curative
approach for end-stage cirrhosis, but this process is associated with
serious problems, such as graft shortage in living-donor-liver
transplantation, surgical complications, organ rejection, and high
cost.3 Although liver ﬁbrosis has traditionally been regarded as
an irreversible process, recent reports indicate that even advanced
ﬁbrosis may be reversible.4 Based on these studies, novel
treatments have been developed to treat patients with cirrhosis.
Thrombocytopenia is a common complication of CLD and is due
to various causes, including decreases in thrombopoietin (TPO)
production, increases in platelet destruction with splenomegaly,
and an inability of bone marrow to perform hematopoiesis.5
Therefore, thrombocytopenia is thought to be intimately related
to the pathogenesis of CLD and cirrhosis.
The effect of thrombocytopenia on liver damage and the exact
mechanisms that lead to thrombocytopenia in CLD and cirrhosis
are still unclear, and further study is required. In our previous
studies, we revealed that platelets play a crucial role in promoting
liver regeneration.6–9
Platelets (anuclear blood cells) are derived from megakaryo-
cytes (MKs), which contain not only proteins needed for hemosta-
sis but also many growth factors that are required for tissue
regeneration and repair.10
We also reported that platelets have a preventive effect on the
progression of liver ﬁbrosis in vitro and in vivo and that the
increase in platelets induced by platelet transfusion can improve
the liver function of patients with CLD and cirrhosis in a clinical
setting.11–14
In addition, it was reported that splenectomy, which is a platelet
increment therapy, contributes to improvement of liver function.15
However, there are many contradictory reports that platelets
have harmful effects on liver ﬁbrosis.16,17
doi:10.1111/jgh.13244
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The aim of this review is to summarize the clinical and experi-
mental studies that have broadened our understanding of the role
of platelets in CLD.
Platelets
Platelets are derived from MKs. MKs are derived from multipotent
hematopoietic stem cells toward MK progenitors. Mature MKs
produce platelets by cytoplasmic fragmentation, which occurs
through a dynamic and regulated process called proplatelet forma-
tion; these proplatelets consist of long pseudopodial elongations
that break in the blood ﬂow.18 Recently, it has been reported that
IL-1α induces thrombopoiesis through MK rupture in response
to acute platelet needs.19
Platelets are discoid and have anucleate structures that contain a
large number of secretory granules,20 alpha granules, dense
granules, and lysosomal granules, of which three types of secre-
tory granules are recognized.
Each granule contains secretory substances, such as platelet-
derived growth factor (PDGF), insulin-like growth factor-1 (IGF-
1), hepatocyte growth factor (HGF), vascular endothelial growth
factor (VEGF), serotonin, adenosine diphosphate (ADP), adenosine
tri-phosphate (ATP), epidermal growth factor (EGF), transforming
growth factor-β (TGF-β), and sphingosine 1-phosphate (S1P).20
Platelets are activated by various types of stimulation and release
active substances from their granules.20–22
Opposite effects have been reported: the positive ones include
processes such as hemostasis,22 wound healing,23 and tissue re-
generation,24 whereas the negative effects of platelet degranulation
include inﬂammation,25 malignancy26 and immune response.27 It
has been reported that platelets accumulate in the liver under cer-
tain pathological conditions, such as ischemia/reperfusion,28,29 cir-
rhosis, cholestasis, 16 viral hepatitis,30 and the residual liver after
hepatectomy.6
Platelets and liver ﬁbrosis
Currently, liver ﬁbrosis is known to be part of a dynamic process
of continuous extracellular matrix (ECM) remodeling in the
setting of chronic liver injury; this process leads to excessive accu-
mulation of several extracellular proteins, proteoglycans, and
carbohydrates.3 Among the cellular populations in the liver,
hepatic stellate cells (HSCs) have been reported to have the most
involvement in liver ﬁbrosis through production of large amounts
of ECM and secretion of TGF-β, which appears to be a key medi-
ator of liver ﬁbrogenesis.3 In the normal liver, HSCs reside in the
space of Disse, and their primary function is storage of vitamin A
and other retinoids.31 In addition, HSCs are now well established
as the key cellular element that is involved in the development
of liver ﬁbrosis. 31 In response to liver injury, HSCs undergo
morphological and functional transdifferentiation, converting from
vitamin A-storing star-like cells into contractile myoﬁbroblastic
cells; this process is called activation.32 Ikeda et al. reported that
human platelets contribute to suppression of both HSC activation
and type I collagen production via a cyclic AMP signaling path-
way in vitro (Fig. 1).33 The level of intracellular cAMP is
increased by adenosine through its receptors on HSCs. Large
amounts of adenosine around HSCs are produced by degradation
of adenine nucleotides, such as ADP and ATP, which are stored
in abundance within the dense granules of platelets.33 Quiescent
HSCs that are inactivated by adenosine may have a decreased abil-
ity to produce TGF-β and secrete ECM. In addition, platelet-
derived HGF plays a critical role in suppression of type I collagen
gene expression in cultured HSCs.34 HGF has also been reported
to attenuate liver ﬁbrosis through suppression of HSC activation
and hepatic TGF-β expression.35 These ﬁndings indicate that
platelets can play a crucial role in suppression of liver ﬁbrogenesis
via inhibition of HSC activation. Because human platelets contain
a smaller amount of HGF than rodent platelets, it is unclear
whether the mechanisms observed in rodents are applicable to
humans.36
Thrombopoietin is the most important growth factor in the
regulation of MK development and platelet production.37 Several
promising novel agents that stimulate TPO receptors and increase
platelet levels, such as eltrombopag and romiplostim, are currently
in development for the treatment of thrombocytopenia in patients
with CLD and cirrhosis. 38,39 The ability to increase platelet levels
could signiﬁcantly reduce the need for platelet transfusions and
facilitate the use of interferon-based antiviral therapy and other
treatments in patients with liver disease.39 Recently, it was
reported that the increase in platelets induced by TPO administra-
tion could improve liver ﬁbrosis, even in subjects with CLD and
cirrhosis, in experimental studies.11,13 Dimetylnitrosamine was
administered three times a week for three weeks to induce liver
ﬁbrosis in rats. Five days after administrating TPO intravenously,
70% hepatectomy was performed, and the liver ﬁbrosis was
compared 24 h after the hepatectomy. The increase in platelets
inhibited the activation of HSCs and reduced the ﬁbrotic area
of the cirrhotic liver; these effects were diminished by adminis-
tration of antiplatelet serum.11 Carbon tetrachloride (CCl4) was
Figure 1 Scheme showing the functions of platelets in the suppres-
sion of liver fibrosis. The signs“↑”and“↓”in the ﬁgure indicate increases
and decreases, respectively. Platelets come in contact with HSCs and
release adenine nucleotides, such as ADP and ATP. These adenine nu-
cleotides subsequently lead to production of adenosine through degra-
dation by HSCs, which inhibits the activation of HSCs. Platelets also
contribute to the expression of HGF in the liver. Quiescent HSCs
inactivated by adenosine or HGF reduce the production of TGF-β and
ECM.
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administered twice a week for 8weeks to induce liver ﬁbrosis in
mice. TPO was administered intraperitoneally once a week from
5 to 8weeks during the experiment. 13By administering TPO,
liver ﬁbrosis was decreased.13 Although the precise mechanisms
that relate the increase in platelets and the liver anti-ﬁbrotic effect
are still unclear, one reason may be that platelets enhanced the
expression of HGF by approximately 14%,11 whereas the matrix
metalloproteinase 9 (MMP9) was enhanced by approximately
three times, thereby stimulating ﬁbrolysis and decreasing pro-
ﬁbrotic growth factor TGF-β. 13 MMPs such as MMP-8, MMP-
9, and MMP-13 possess the ability to degrade the extracellular
matrix via the breakdown of collagen type I.40 MMP-9 may indi-
rectly contribute to ﬁbrolysis by accelerating HSC apoptosis.41 In
the murine bile duct ligation model, thrombocytopenia exacer-
bates liver ﬁbrosis and platelets have an anti-ﬁbrotic role by sup-
pressing type I collagen expression via the HGF–Met signaling
pathway.34 Recently, Takahashi et al. reported that transfused
human platelets improved liver ﬁbrosis in severe combined im-
mune deﬁciency (SCID) mice induced by CCL4.42 An increase
in murine HGF and a decrease in TGF-β were observed in the
liver.42 Although the precise mechanism that relates the increase
in platelets and liver ﬁbrolysis remain unclear, one reason is that
platelets enhanced the expression of HGF without an increase in
the expression of pro-ﬁbrotic growth factors derived from plate-
lets, such as TGF-β and PDGF, in the cirrhotic liver in rodent
models.11,35
Platelets and liver regeneration
Liver regeneration is performed by proliferation of hepatocytes,
biliary epithelial cells, liver sinusoidal endothelial cells (LSECs),
Kupffer cells, and hepatic stellate cells, all of which proliferate
to rebuild the lost hepatic tissue.43 Intercellular interactions via
many growth factors and cytokines, including HGF, tumor necro-
sis factor-α (TNF-α), interleukin-6 (IL-6), transforming growth
factor-α (TGF-α), and EGF, play important roles. Each growth fac-
tor and cytokine leads to subsequent activation of downstream
transcription cascades, which is associated with the transitions of
quiescent hepatocytes into the cell cycle and progression beyond
the restriction point in the G1 phase of the cycle.43 Several tran-
scription factors are known to have functions in this process:
nuclear factor-kappa B (NF-κB), activator protein 1 (Ap-1),
CCAAT/enhancer binding protein-b (C/EBPb), extracellular
signal-regulated kinase 1/2 (ERK 1/2),44 signal transducer and
activator of transcription 3 (STAT3), and phosphatidylinositol-3-
kinase (PI3 K)/Akt.45 The current study focused on the TNF-α/
NF-κB, IL-6/STAT3, and PI3 K/Akt pathways as the three major
cascades in which platelets exert their effects during the process
of liver regeneration.
The TNF-α/NF-κB pathway is activated within 30min after
hepatectomy, and the activation usually lasts 4–5 h. NF-κB is
found in almost every cell, including hepatocytes and non-
parenchymal cells. It is usually inactivated by Inhibitor of
NF-κB (IκB), which binds to the p65 subunit.46 After NF-κB is
stimulated by TNF-α and activated by removal of IκB from the
p65 subunit, it migrates to the cell nucleus and binds to the pro-
moter of cyclin-D1, which regulates the G0/G1-to-S-phase transi-
tion.47 STAT3 is activated 1–2 h after hepatectomy and lasts 4–6 h.
STAT3 is phosphorylated after being stimulated by IL-6 and
translocates to the nucleus, where it promotes the expression of
cyclin-D1 and p21 to control the progression of the cell cycle.48
Haga et al.reported that hepatocytic mitosis was signiﬁcantly sup-
pressed in STAT3- knockout mice after partial hepatectomy.49 The
PI3 K/Akt pathway was activated shortly after hepatectomy. The
pathway is stimulated by HGF, IL-6, TNF-α, TGF-α, or many
other signaling molecules.50 C-met is one of the tyrosine kinase
receptors on the surface of hepatocytes that binds with HGF, and
HGF/c-met signaling activates PI3 K, which recruits Akt to the site
of membranes and, subsequently, phosphorylates Akt.51 Phos-
phorylation of Akt results in activation of glycogen synthase
kinase (GSK) 3b, thus resulting in accumulation of β-catenin and
cyclin-D1 in the nucleus, and induces DNA synthesis and cellular
mitosis of hepatocytes.52
However, it has never been directly demonstrated that release of
growth factors from platelets is responsible for platelet-mediated
stimulation of liver regeneration in vivo.53,54
Mechanisms for the promotive effect of
platelets in liver regeneration
The direct effect of platelets. Platelets accumulate in the
thrombocytotic liver within 5min after hepatectomy, and a two-
fold increase in platelets is observed in the liver in comparison
with pre-hepatectomy levels. 55 Electron microscopy has revealed
that platelets translocate from the sinusoidal space into the space of
Disse and have direct contact with hepatocytes.6,7 Endo et al.56 re-
ported a similar phenomenon, in which platelets accumulate in the
liver and a large number platelets are detected in the space of Disse
in response to the administration of lipopolysaccharide (LPS),
interleukin-1, and TNF-α. Intravital microscopy reveals that al-
though a few platelets ﬂow rapidly in the liver sinusoids before
partial hepatectomy, a signiﬁcant number of platelets accumulate
in the liver sinusoids, and the platelets ﬂow slowly with rolling
and adhering after hepatectomy.8 These results suggest that plate-
lets accumulate in the liver within a few minutes after hepatectomy
and provide signals for rapid hepatocyte proliferation through di-
rect contact with hepatocytes. A co-culturing chamber system
was used to clarify the role of the direct contact of platelets with he-
patocytes. Platelets and hepatocytes are separated by a permeable
membrane.10 Direct contact between platelets and hepatocytes trig-
gers the release of soluble mediators from platelets, such as HGF,
IGF-1, and VEGF, which leads to hepatocyte proliferation (Fig. 2).
The mechanism that underlies the direct effect of platelets can
be explained. Platelets accumulate in the liver immediately after
hepatectomy, translocate from the liver sinusoids to the space of
Disse and release growth factors, such as HGF, IGF-1, and VEGF,
through direct contact with hepatocytes. Growth factors stimulate
the initiation of hepatocyte mitosis, which eventually promotes
liver regeneration. Human platelet does not include most of the
HGF; 36 thus, IGF-1 is considered to be the most important medi-
ator for liver regeneration in human platelets. Recently, it has been
reported that RNA transfer mechanism as an additional contributor
to platelet-mediated liver regeneration.57
The collaborative effect with Kupffer cells. Kupffer
cells play a role in the liver as macrophages that act against
bacteria, endotoxins, and microbial debris derived from the
T. Kurokawa et al. Platelets and chronic liver disease
747Journal of Gastroenterology and Hepatology 31 (2016) 745–751
© 2015 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
gastrointestinal tract. Kupffer cells produce important cytokines
that have a stimulatory inﬂuence on hepatocyte proliferation after
hepatectomy.58 One of the most important events following hepa-
tectomy is an increase in the plasma levels of TNF-α. An experiment
using an antibody against TNF-α demonstrated a signiﬁcant reduc-
tion of hepatocyte proliferation,59 and mice lacking the TNF-α
receptor exhibit severe impairment in liver regeneration after hepa-
tectomy.60 Activation of the TNF-α receptor increases the hepatic
expression of the NF-κB in both hepatocytes and non-parenchymal
cells and is followed by production and release of IL-6 from Kupffer
cells.43 Kupffer cells are considered to be the most important source
of both TNF-α and IL-6. Kupffer cell-depleted mice fail to exhibit
increases in TNF-α and IL-6 to levels that are equivalent to those
in mice with Kupffer cells after hepatectomy.61 The interrelationship
between platelets and Kupffer cells has been well studied using
ischemia/reperfusion models. A triangular interaction among plate-
lets, Kupffer cells, and leukocytes has been demonstrated as the
major mechanism of injury.62 Rats depleted of Kupffer cells were
subjected to ischemia/reperfusion, which suppressed platelet ad-
herence in sinusoids, and, as a consequence, there was attenua-
tion of sinusoidal perfusion failure and endothelial damage. 29
Tamura et al.63 reported that platelets adhered to Kupffer cells
at the early period of ischemia/reperfusion and that the platelets
that adhered Kupffer cells were involved in apoptosis of hepato-
cytes and the mechanism of hepatic ischemia/reperfusion injury.
Nakamura et al. described different characteristics for platelets
and Kupffer cells. The authors reported that direct cellular inter-
actions between platelets and Kupffer cells play an important
role in platelet migration to the space of Disse after administra-
tion of LPS.64 It is therefore likely that platelets are activated by
direct contact with Kupffer cells, and Kupffer cells are stimu-
lated by direct contact with platelets. The collaborative effect
of platelets with Kupffer cells on liver regeneration is thought
to occur after hepatectomy, when activated Kupffer cells induce
accumulation and activation of platelets in the liver, and the
functions of Kupffer cells are enhanced by the accumulated
platelets. Liver regeneration is promoted by the direct effect of
growth factors released from platelets and by the paracrine ef-
fect of Kupffer cells, which is enhanced by the platelets (Fig. 2).
The cooperative effect with liver sinusoidal endo-
thelial cells. Sinusoidal cells account for 70% of LSECs.
The construction of a thin and continuous layer of sinusoidal endo-
thelium forms a structural barrier that separates the hepatic paren-
chyma from blood constituents that pass through the liver.65
LSECs enable contact between circulating blood and hepatocytes
and help exchange various soluble macromolecules and nanoparti-
cles, such as lipoproteins.66 LSECs are involved in liver regenera-
tion and produce immune-regulatory and pro-inﬂammatory
cytokines, including HGF, IL-1, IL-6, and interferons. The eleva-
tion of the IL-6 concentration after hepatectomy is an important
component of the early signaling pathways in liver regeneration,
and IL-6 activates the acute phase of protein synthesis by hepato-
cytes as a part of the overall inﬂammatory response.67 The
plasma IL-6 concentration increases after hepatectomy from
6 h, with a peak by 24 h.68 IL-6 binds to the receptor on hepato-
cytes, which leads to phosphorylation of STAT3 monomers.
The relationship between platelets and LSECs is well docu-
mented in ischemia/reperfusion models.69 In contrast, no studies
have focused on the relationship between platelets and LSECs in
liver regeneration. The role of platelets in liver regeneration in
relation to LSECs was evaluated using co-culturing chamber
systems.9 These studies clariﬁed that platelets increase the prolif-
eration of LSECs and induce IL-6 release from LSECs, and IL-6
derived from LSECs accelerates DNA synthesis in hepatocytes.
Direct contact between platelets and LSECs was required for
IL-6 excretion. In addition, the high level of sphingosine-1-
phosphate (S1P) in platelets plays an important role in IL-6
secretion.9 S1P is a lipid mediator that regulates diverse biologi-
cal processes, including proliferation, migration, and cytoskeletal
reorganization.70 S1P is excreted in large amounts from activated
platelets and interacts with endothelial cells under the conditions
of critical platelet-endothelial interactions, such as thrombosis,
angiogenesis, and atherosclerosis.70
Figure 2 Liver regeneration promoted by plate-
lets. Platelets accumulate in the liver immediately
after hepatectomy. Platelets translocate from the
sinusoidal space to the space of Disse and release
growth factors, such as IGF-1 and HGF, through di-
rect contact with hepatocytes, which, subse-
quently, induces initiation of hepatocyte mitosis.
Direct contact between platelets and LSECs trig-
gers the release of S1P from platelets, which leads
to excretion of IL-6 from LSECs. IL-6 from LSECs
promotes proliferation of hepatocytes, and interac-
tion of Kupffer cells (KCs) with platelets activates
KCs after hepatectomy. Activated KCs release
TNFα and IL-6. IGF-1 and HGF activates Akt and
ERK1/2 in the hepatocytes. IL-6 stimulates STAT3
activation. These signal transduction molecules
proliferate hepatocytes.
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The cooperative effect of platelets with LSECs on liver regener-
ation occurs when direct contact between platelets and LSECs
induces S1P release from platelets, which subsequently induces
excretion of IL-6 from LSECs. IL-6 derived from LSECs promotes
hepatocyte proliferation through the STAT3 pathway (Fig. 2).
Effect of platelet transfusion on chronic liver
disease and cirrhosis. Platelet transfusion is an established
therapy for thrombocytopenia, with well-known beneﬁts and com-
plications. The results suggest that both endogenous and
exogenous platelets may play a role in the improvement of liver
function, although whether platelet transfusion is appropriate for
CLD patients with thrombocytopenia is still unclear, even in the
published guidelines for platelet transfusion.71 Based on these an-
imal experiments, clinical trials were performed. Maruyama et al.
recently reported on a clinical trial to investigate whether platelet
transfusion improves liver function in patients with CLD and cir-
rhosis (Child-Pugh class A or B) who all presented with thrombo-
cytopenia (platelet counts between 50 000 and 100 000/μL). The
subjects received 10 units of platelet concentrate once per week
for 12weeks. One and three months after the last transfusion,
signiﬁcant improvements in serum albumin were observed (Fig. 3).
Serum cholinesterase improved for 9months after the last transfu-
sion. Serum hyaluronic acid, which represents liver ﬁbrosis, exhib-
ited a tendency to improve after the last transfusion. This clinical
trial was a non-controlled, non-randomized study, in which only
6 patients were eventually analyzed.14
Limitations of platelet increment therapy
for CLD and cirrhosis
Platelet increment therapies, such as administration of a TPO receptor
agonist, splenectomy, and platelet transfusion, have been reported to
have adverse effects, although they have ameliorating effects for
CLD and cirrhosis.39,72,73 Portal vein thrombosis has been observed
among patients who received eltrombopag or splenectomy.39 In addi-
tion, operative complications of splenectomy include hemorrhage,
infection, and injury to the pancreatic tail.72 In platelet transfusion,
platelets are frequently activated and may induce inﬂammatory reac-
tions and unexpected side-effects, including febrile non-hemolytic re-
actions and acute lung injury.73 There are some reports regarding the
detrimental effects of platelets on CLD and cirrhosis. Zaldivar et al.
provided evidence that chemokine (C-X-C motif) ligand 4 (CXCL4),
which is known as a platelet-derived factor, modulated liver ﬁbrosis
in animal models of chronic liver injury in vivo, although direct re-
lease of CXCL4 by platelets was not demonstrated.16 In addition,
the proliferation and chemotactic migration of HSCswas signiﬁcantly
enhanced by CXCL4 without synthesis of collagen and expression of
TGF-β in vitro 16 As one of the side-effects of platelet increment ther-
apy, promotion of liver carcinogenesis should be considered because
of the high risk of HCC in patients with CLD and cirrhosis 3 Carr
et al. reported that patients with thrombocytosis (platelet
levels> 400×109/L) had larger HCC sizes and better liver function
than patients with platelet levels in the normal range.74 Sitia et al.
demonstrated that antiplatelet drugs reduced the development of
HCC in a mouse model of chronic hepatitis B virus infection, al-
though this approach was not effective in the carbon tetrachloride-
induced cirrhosis model.75 These ﬁndings indicate that platelets might
have a promotive effect on liver carcinogenesis. However, it has been
reported that TPO itself had no proliferative effect on HCC in in vitro
and in vivo experiments.76 Currently, two TPO-R agonists,
eltrombopag and romiplostim, have been approved for treatment of
chronic immune thrombocytopenic purpura. Eltrombopag is a
small-molecule, non-peptide TPO-R agonist, whereas romiplostim
is a peptide TPO-R agonist that is composed of an IgG Fc fragment.77
The efﬁcacy of eltrombopag in hepatitis C virus-infected patients with
thrombocytopenia before the initiation of pegylated interferon and ri-
bavirin therapy has previously been reported 38 In contrast to TPO,
eltrombopag does not activate the PI3K/Akt pathway.78 Another re-
port demonstrated that eltrombopag has no proliferative effect in
myelodysplastic syndromes and AML patients but rather inhibits
the proliferation of the leukemia cell line.79 Thus, eltrombopag would
be secure in HCC, and use of this type of TPO-R agonist can be
anticipated as a novel treatment for liver disease.
Summary and future work
This review discussed the current evidence for platelets improving
liver ﬁbrosis and promoting liver regeneration. There is signiﬁcant
evidence that platelets play a role in improving ﬁbrosis. ATP and
ADP inside platelets are degraded by HSCs, and adenosine is in-
corporated into the HSCs. Cyclic AMP is increased by adenosine,
and HSCs become inactivated by cyclic AMP. There are three dif-
ferent mechanisms of liver regeneration induced by platelets: a di-
rect effect on hepatocytes; cooperation with Kupffer cells; and a
cooperative effect with LSECs. Therefore, platelet therapy, that
is, platelet transfusion and TPO receptor agonist administration,
could open a new avenue to develop novel strategies for treatment
of liver diseases for which there is currently no effective treatment
except transplantation
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Figure 3 Liver function improvements after platelet transfusion. The
serum albumin level at 1 month (P = 0.03) after the last transfusion was
signiﬁcantly greater than that before the platelet transfusion. The data
are expressed as the means ± standard deviations. *P< 0.05 compared
with the levels before the platelet transfusion.
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